The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potentia
about
Structure and Protein-Protein Interactions of Human UDP-GlucuronosyltransferasesA humanized UGT1 mouse model expressing the UGT1A1*28 allele for assessing drug clearance by UGT1A1-dependent glucuronidationMetabolic drug-drug interaction potential of macrolactin A and 7-O-succinyl macrolactin A assessed by evaluating cytochrome P450 inhibition and induction and UDP-glucuronosyltransferase inhibition in vitro.Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT).Enantiomer selective glucuronidation of the non-steroidal pure anti-androgen bicalutamide by human liver and kidney: role of the human UDP-glucuronosyltransferase (UGT)1A9 enzymeCorrelation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors.Albumin stimulates the activity of the human UDP-glucuronosyltransferases 1A7, 1A8, 1A10, 2A1 and 2B15, but the effects are enzyme and substrate dependent.The role of quantitative ADME proteomics to support construction of physiologically based pharmacokinetic models for use in small molecule drug development.Interactions between buprenorphine and the protease inhibitors darunavir-ritonavir and fosamprenavir-ritonavir.Methadone inhibits CYP2D6 and UGT2B7/2B4 in vivo: a study using codeine in methadone- and buprenorphine-maintained subjects.Evaluation of 3,3',4'-trihydroxyflavone and 3,6,4'-trihydroxyflavone (4'-O-glucuronidation) as the in vitro functional markers for hepatic UGT1A1.Accurate prediction of glucuronidation of structurally diverse phenolics by human UGT1A9 using combined experimental and in silico approaches.First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics.Regioselective glucuronidation of flavonols by six human UGT1A isoforms.Drug-Drug Interactions Potential of Icariin and Its Intestinal Metabolites via Inhibition of Intestinal UDP-Glucuronosyltransferases.Drug-Drug Interaction Potentials of Tyrosine Kinase Inhibitors via Inhibition of UDP-Glucuronosyltransferases.Altered UDP-glucuronosyltransferase and sulfotransferase expression and function during progressive stages of human nonalcoholic fatty liver disease.Bioactivation of Heterocyclic Aromatic Amines by UDP Glucuronosyltransferases.Scaling factors for the in vitro-in vivo extrapolation (IV-IVE) of renal drug and xenobiotic glucuronidation clearanceIn vitro and in vivo small intestinal metabolism of CYP3A and UGT substrates in preclinical animals species and humans: species differences.Substrate inhibition kinetics in drug metabolism reactions.Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results.The role of drug metabolizing enzymes in clearance.Biotransformation of xenobiotics in the human colon and rectum and its association with colorectal cancer.Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions-an Industry Perspective.Human UDP-Glucuronosyltransferase (UGT) 2B10: Validation of Cotinine as a Selective Probe Substrate, Inhibition by UGT Enzyme-Selective Inhibitors and Antidepressant and Antipsychotic Drugs, and Structural Determinants of Enzyme Inhibition.A Fragment-Based Approach for the Computational Prediction of the Nonspecific Binding of Drugs to Hepatic Microsomes.In Vitro Inhibition of Human UDP-Glucuronosyl-Transferase (UGT) Isoforms by Astaxanthin, β-Cryptoxanthin, Canthaxanthin, Lutein, and Zeaxanthin: Prediction of in Vivo Dietary Supplement-Drug Interactions.Cyp3a11-mediated testosterone-6β-hydroxylation decreased, while UGT1a9-mediated propofol O-glucuronidation increased, in mice with diabetes mellitus.Identifying and applying a highly selective probe to simultaneously determine the O-glucuronidation activity of human UGT1A3 and UGT1A4.Mass spectral analysis of the multikinase inhibitor BZG and its metabolites and analysis of their binding to vascular endothelial growth factor receptor-2.How to Choose In Vitro Systems to Predict In Vivo Drug Clearance: A System Pharmacology Perspective.Prediction of Metabolic Interactions With Oxycodone via CYP2D6 and CYP3A Inhibition Using a Physiologically Based Pharmacokinetic Model.Safety and pharmacokinetics of the CIME combination of drugs and their metabolites after a single oral dosing in healthy volunteers.The Human UDP-glucuronosyltransferase UGT2A1 and UGT2A2 enzymes are highly active in bile acid glucuronidation.Mass balance, metabolite profile, and in vitro-in vivo comparison of clearance pathways of deleobuvir, a hepatitis C virus polymerase inhibitor.In vitro metabolism of jaceosidin and characterization of cytochrome P450 and UDP-glucuronosyltransferase enzymes in human liver microsomes.In vitro evidence for bakuchiol's influence towards drug metabolism through inhibition of UDP-glucuronosyltransferase (UGT) 2B7.A high throughput assay for the glucuronidation of 7-hydroxy-4-trifluoromethylcoumarin by recombinant human UDP-glucuronosyltransferases and liver microsomes.Using human recombinant UDP-glucuronosyltransferase isoforms and a relative activity factor approach to model total body clearance of laropiprant (MK-0524) in humans.
P2860
Q28071266-FA2B40AB-BC7B-46D8-919B-52E94FD4B380Q33861874-35133991-2B4A-4BC4-A90E-CE180884B607Q34057508-5FC1B15D-396F-4AC5-996F-8317983431B3Q34325249-DD5299CB-09EC-4D23-8ADD-EE25C44965CDQ34335228-DF29BB78-A80F-483F-86B2-9E5181184A53Q34551930-9AEFA81E-8C7B-44F2-995F-72957EDF5C66Q34571313-29214BC0-439E-4B9B-B268-8906366B73B5Q35560052-B2529012-66DA-4076-8F22-C75D237E5331Q35672530-9EC63920-BA79-40D2-92B8-EB45FF8F7CF3Q36111225-7F1C3F60-AD21-4808-83F1-FFA653054290Q36115752-46489E17-90CD-4FF1-8B35-7D4BCB82A056Q36132276-AFF19E49-0ADB-454F-ACCE-159F5020D3A8Q36132293-D2DFB619-FFCB-4588-882D-B184D722E358Q36185254-EC848270-3ED6-44CF-957B-FF56FCC24EF4Q36344087-484D953F-BEFD-42AB-B0FF-569FDAFD63F7Q36353657-B5E2570C-457C-4FC5-B4A1-27EBCBE0D9F7Q36642354-9C3E13CF-DA91-4633-B2DB-FA37A519CF72Q36905502-3D6E512C-1A94-45FA-894E-DBA13770964AQ36924729-53C5C9CA-50DA-488C-979A-96E32AF26552Q37920916-66F808D7-18EA-496F-99B2-34655C7CDDDBQ37941118-6E488BDA-2A32-45DE-8249-DC3BFA861E49Q38016204-8E94711F-A80B-465B-8C0F-A5CD595FCB96Q38176051-E5483750-CD0F-4012-9272-688A28488C48Q38357424-A93F79E1-BC6F-48FA-898F-C87103422D3AQ38800092-0E747242-6BCA-4363-9189-3C603E555F04Q38811693-9410EC6F-7172-41F7-9DFA-6072A9596DA9Q39471808-0AEF557E-E0EC-4E4A-902C-331CE3535086Q39486132-AC47FF93-462A-4A23-9733-A2695985F4BCQ39499152-D9E4DE19-5591-49B4-AA2C-22A1E483732AQ39736342-22687053-328B-43BE-981D-5930C4B95195Q40248432-73A5CED8-0F60-4855-8FE5-28B5BFA345A0Q40353496-C2E67CFD-DB92-4A8E-BA6D-D7821FA12ED3Q41678423-12E87E5A-44A4-49AC-84A5-58CF787AD2BAQ41737190-EED39637-EAF5-48C2-B56B-1458CE6EC7C3Q41779856-83B816A9-8F32-439A-9803-F77DEF671B3EQ41839207-6BB2EA6C-7233-4467-8CA0-B933BFB251E7Q42769916-0D6DB83A-9EC4-453D-816F-1B51EB84A534Q42961853-F037FF89-BCBB-479B-BC7C-799F49DE7B8EQ43511287-29B0CDAE-1DE2-43F4-AB73-E89389061A7CQ43730577-D213DA03-478D-4EC7-ABA0-766BD3E9A1A4
P2860
The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potentia
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
The prediction of drug-glucuro ...... drug-drug interaction potentia
@en
The prediction of drug-glucuro ...... drug-drug interaction potentia
@nl
type
label
The prediction of drug-glucuro ...... drug-drug interaction potentia
@en
The prediction of drug-glucuro ...... drug-drug interaction potentia
@nl
prefLabel
The prediction of drug-glucuro ...... drug-drug interaction potentia
@en
The prediction of drug-glucuro ...... drug-drug interaction potentia
@nl
P2860
P1476
The prediction of drug-glucuro ...... drug-drug interaction potentia
@en
P2093
John O Miners
Kathleen M Knights
P2860
P304
P356
10.3109/03602530903210716
P407
P577
2010-02-01T00:00:00Z